3 active not recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 3 |
Follow Episodic Migraine: new trials by email Literature Review of Episodic Migraine trials Research Report on Episodic Migraine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine Xeomin, Placebo - Episodic Migraine | Phase 3 | Active not recruiting | Merz Therapeutics GmbH | 997 | 2025-08-21 | 2026-10-14 |
| A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults Botulinum toxin type A, Placebo - Episodic Migraine | Phase 3 | Active not recruiting | Ipsen | 751 | 2023-09-29 | 2026-09-04 |
| A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine Galcanezumab, Placebo - Episodic Migraine | Phase 3 | Active not recruiting | Eli Lilly and Company | 533 | 2018-03-14 | 2026-01-26 |
Headache (1)
Neurologic Manifestations (1) · Pain (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Botulinum Toxins, Type A (2) · abobotulinumtoxinA (1) · galcanezumab (1) · incobotulinumtoxinA (1)
Eli Lilly and Company (1) · Ipsen (1) · Merz Therapeutics GmbH (1)
Germany (3) · Spain (3) · United States (3) · Canada (2) · Czechia (2) · Denmark (2) · France (2) · Italy (2) · Poland (2) · Austria (1) · Georgia (1) · India (1) · Japan (1) · Mexico (1) · Netherlands (1)
2017 (1), 2023 (1)